Items where Author is "Fattahi, M. R."

Article

(2020) SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Clinical Infectious Diseases. pp. 2206-2212. ISSN 1058-4838

(2020) The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. Journal of Gastroenterology and Hepatology. pp. 1590-1594. ISSN 0815-9319

(2019) The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients. Asian Pac J Cancer Prev. pp. 2311-2317. ISSN 2476-762X (Electronic) 1513-7368 (Linking)

(2019) The combination of sofosbuvir and daclatasvir is well tolerated and extremely effective in treating patients with hepatitis C with severe renal impairment including hemodialysis patinets. Journal of Hepatology. E233-E233. ISSN 0168-8278

(2018) SD1000: 96.4 SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. Journal of Viral Hepatitis. pp. 198-199. ISSN 1352-0504

(2016) Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepatitis Monthly. ISSN 1735-143X